E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers N > Headlines for NovaBay Pharmaceuticals, Inc. > News item
Published on 3/19/2014 in the Prospect News PIPE Daily.

NovaBay Pharmaceuticals to price public offering of stock, warrants

Company names Laidlaw & Co. (UK) as underwriter

By Marisa Wong

Madison, Wis., March 19 - NovaBay Pharmaceuticals, Inc. plans to price a public offering of common stock and warrants, according to a 424B5 filing with the Securities and Exchange Commission.

Laidlaw & Co. (UK) Ltd. will be the underwriter.

Proceeds will be used for working capital and general corporate purposes, including research and development, clinical trials and selling, general and administrative expenses.

NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company based in Emeryville, Calif.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.